Roundtable On Coronavirus Pharma Industry Impact In China, Korea, - - PowerPoint PPT Presentation

Roundtable On Coronavirus Pharma Industry Impact In China, Korea, And Japan

Discussing experiences and lessons across East Asia

Speakers

2

Ian Haydock Editor-in-Chief, Pharma Insights, APAC Pharma Intelligence (Tokyo) Jung Won Shin Senior Reporter, Insights, APAC Pharma Intelligence (Seoul) Brian Yang Senior Editor, Insights, APAC Pharma Intelligence (China) Moderator Panelists

Agenda

Informa Pharma Intelligence 3

Region-Specific Insights into:

• Current Local Situation
• Industry Response & Impact
• R&D Activity
• Policy & Regulatory Approaches

& Lessons

Common Themes? Q&A

China and COVID-19: Treatments, Vaccines and Lessons Learned

Brian Yang Brian.Yang@informa.com

Wuhan lockdown on Jan.23 - drastic measures spread to Beijing and most of the country Beijing remained in lockdown until early May Fast approval of viral testing kits and antiviral and other drugs Second wave fear, social tracing, massive testing and fast vaccine development

China Emerges Early from COVID

Photos: Brian Yang

5

China: Antiviral trials

• Early start for several leading antivirals
• Local trials for Gilead’s remdesivir
• Others: hydroxychloroquine, Avigan (favipiravir)

Leading Vaccines Race

• Out of 16 vaccines currently in clinical studies

globally, five are from China

• CanSino, state-owned Sinopharm leading the

pack with Phase III trials

• Year-end approval likely and “public good” as

promised by authorities

China: Lessons Learned

• Less prepared even after SARS outbreak in 2003
• Quick approval of testing kits allowed early and

mass testing

• Slow easing of lockdowns restrictions, 100%

mask-wearing and social tracing

• Combination with traditional medicines in

treating COVID patients

Questions Remain

• China has not authorized antivirals for COVID,

instead relying on traditional medicines

• Most vaccines based on inactivated virus, an old

technology

• New drugs in pipeline: antibodies among others

10

Thank You

Brian Yang Brian.Yang@informa.com

Japan and COVID-19

Ian Haydock Ian.Haydock@informa.com

Relatively Low Case Numbers

• Attributed to high compliance with voluntary

lock-down (social responsibility)

• Familiarity with mask-wearing in public
• Targeted testing/tracing of clusters

Industry Impact

• Still early – some trial recruitment affected but

impact unclear

• Ongoing need for chronic drugs for serious

diseases

• Uptake of new tools? Remote rep ‘visits’, online

Dr education, smaller salesforce?

R&D Activity

• Antivirals – Avigan (late July data?) Trial

recruitment issues

• Plasma/antibody therapies – Takeda, Chugai
• Vaccines – Shionogi/UMN (rDNA) and AnGes

(DNA): H1/Q3 ‘21?

• New ‘Fugaku’ supercomputer screening for

drugs

Regulatory Approaches

• Rapid emergency approval of Dx and Gilead’s

remdesivir (just days)

• Clear guidance on fast-track system and

regulatory responsibilities

• PMDA sees provision of pandemic solutions as

top priority

South Korea and COVID-19

Jung Won Shin Jungwon.Shin@informa.com

South Korea

• Overview
• Policy & Regulatory
• Pharma R&D Activity

Common Themes?

Product name goes here – i.e. Citeline 18

Respond To Unique Local Situation Leverage National Expertise Be Fast, Be Flexible Value Of Supportive Regulators Regional Collaboration On Antibodies, Antivirals

19

Q&A

Thank You!